Your pipeline decisions deserve better than a spreadsheet.
PortiVix gives pharma teams one governed place to see what is moving, what is stuck, who owns it, and what needs a decision - across molecule strategy, project execution, risk, financials, material readiness, and audit evidence.
- Cloud-hosted
- SSO-ready
- Capability-level RBAC
- Protected audit log
The cost of the status quo
Status is always a week behind.
Go/kill evidence is scattered across teams.
Ownership gaps hide in email threads.
Audit evidence is rebuilt when it is already needed.
Pharma portfolio governance has outgrown disconnected tools.
Four pressures are making governed, risk-adjusted, audit-ready decisions non-optional.
Thin pipelines, patent cliffs
Every asset decision carries more weight. Go/kill calls and phase gates cannot wait for a status pack.
Capital discipline
Leadership needs risk-adjusted value - eNPV, not optimistic NPV - before committing spend.
Regulatory & audit scrutiny
Evidence has to exist before an inspection, not be reconstructed from folders after one.
AI raised the bar
Buyers expect intelligence and traceability, not another spreadsheet with a dashboard on top.
Every review cycle, your most experienced people are compiling instead of deciding.
PMO teams rebuild status packs from emails, spreadsheets, shared drives, Gantt exports, and team calls. By the time leadership sees the pack, the work has already moved. Risks were raised somewhere. Approvals happened somewhere. Material delays were discussed somewhere. But the decision record is not complete when the decision is being made.
PortiVix turns pharma portfolio work into a governed operating model.
It connects the full journey: molecule records, phase gates, portfolio and programme health, project plans, workstreams, risks, issues, NPV/eNPV, material readiness, resource utilisation, reports, and audit evidence.
When a milestone slips, leadership sees the impact.
When a risk changes, the record stays attached.
When a decision is made, the evidence is already there.
Two connected dimensions: portfolio decisions and project execution.
The same governed record carries molecule intelligence, risk, and value - and the milestone-to-activity plan, critical path, risks, and issues that deliver it.
- Phase
- Ph II · active
- PTRS
- 68%
- Patent (DS)
- 2031
- eNPV
- $412m
Built for the decision moments pharma teams actually run.
PortiVix maps to the reviews your organisation already holds - and makes the evidence ready before each one.
Weekly project review
Overdue work, upcoming milestones, blocked tasks, task owners, comments, risks, issues, and approval queues.
Monthly portfolio review
Programme health, molecule status, cross-portfolio risk, execution drift, resource pressure, financial signals, and decision items.
Phase-gate review
PTRS, Business Risk, IP Risk, API/Supply Risk, KSM scores, NPV/eNPV, commentary, and go/kill evidence.
Regulatory milestone review
Filing category, submission milestones, approval evidence, audit trail, document links, and date variance.
Material & supply readiness review
Material quantities, vendor records, lead times, country of origin, budget, and version history.
One truth. Every governance moment.
The same connected record powers every review - no re-compiling between them.
Explore the platformTask-level work rolls up. Leadership decisions flow down.
Progress captured at the activity level becomes portfolio visibility - so governance is a by-product of the work, not a separate exercise.
platform pillar
Molecule intelligence
A single asset record for commercial, regulatory, patent, phase, risk, financial, material, and decision history.
platform pillar
Portfolio governance
Live portfolio, programme, and molecule visibility for leadership and PMO teams.
platform pillar
Project execution
Milestones, tasks, subtasks, activities, dependencies, workstreams, ownership, approvals, comments, and documents.
platform pillar
Risk and issue control
PTRS, Business, IP, API/Supply, KSM, project risks, issue tracker, escalation, and control tower views.
platform pillar
Financial and supply readiness
NPV/eNPV, cashflow actuals, material composition, vendor planning, lead times, and supply exposure.
platform pillar
Audit-ready operations
RBAC, SSO, protected audit logging, actor identity, exportable records, and 21 CFR Part 11 readiness support.
The principle behind PortiVix
“We don’t build software to sell dashboards. We build products that make pharma decisions defensible - so a molecule call made today still holds up when someone asks ‘what changed?’ years from now.”
VirtuNx · Founding principle
Different teams need different views of the same truth.
Leadership, PMO, and delivery teams get the context they need without forcing everyone into the same dashboard.
CXO / Head of R&D
Fewer surprises before portfolio reviews.
What you deal with today
See pipeline health, risk, financial value, and execution readiness before decisions are due.
What changes with PortiVix
A live leadership view of what is moving, what is stuck, and what needs a decision - without waiting for a manually assembled pack.
PMO Leads
Stop compiling. Start governing.
What you deal with today
Days rebuilding the same status pack from emails, spreadsheets, and calls.
What changes with PortiVix
Live governance dashboards replace weekly pack reconstruction and ownership chasing.
Project Managers
Every task owned. Every deadline visible.
What you deal with today
Chasing status instead of leading delivery.
What changes with PortiVix
Governed project plans with milestones, tasks, subtasks, dependencies, critical path, risks, and issues.
A task tracker was never built to govern a pharma pipeline.
PortiVix is built around pharma assets, phase gates, go/kill decisions, risk scoring, NPV/eNPV, material readiness, regulatory evidence, and cross-functional execution.
Spreadsheets & generic PM tools
Excel · MS Project · Smartsheet · generic PPM
PortiVix
Pharma portfolio & project governance
Track tasks and deadlines.
Connect molecule strategy, phase gates, risk, finance, materials, resources, projects, and audit evidence.
Require manual status consolidation for leadership.
Roll progress, risks, issues, and milestones into portfolio and programme views.
Treat audit as an export or afterthought.
Create traceability as work happens, with actor identity and change history.
Do not understand pharma asset decisions.
Built around molecule records, go/kill scoring, NPV/eNPV, patent fields, material readiness, and regulatory evidence.
Flexible but often ungoverned.
Configurable, but controlled through RBAC, approval workflows, templates, audit trail, and tenant settings.
Built for regulated pharma environments. Ready for enterprise scale.
Cloud-ready, SSO-ready, RBAC-driven, audit-trailed, and tenant-isolated - designed for organisations that need secure operations and defensible records.
Cloud
Cloud-hosted with UK, EU, and US region options
Identity
SSO-ready: SAML 2.0 and OAuth 2.0
Access
Capability-level RBAC and project-level access rules
Security
MFA, encrypted data, secure token model, rate limiting
Compliance support
Audit trail, actor identity, checksum verification, exportable logs, 21 CFR Part 11 readiness support
Deployment
Cloud, private cloud, and on-premise options subject to scoping
We are onboarding a small group of pharma design partners.
PortiVix is built with pharma teams, not just for them. We work closely with a limited number of organisations to map the platform to how they actually run portfolio reviews, phase gates, and audits - before wider release.
- Shape the roadmap around your real governance rhythms
- Hands-on onboarding with a named implementation contact
- Preferential early-partner terms
See your portfolio operating model in PortiVix.
We do not start with a generic demo. We map your portfolio, molecule, project, approval, reporting, and governance workflows first - then show how PortiVix would work for your organisation.